Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: A role of NADPH oxidase 2

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 441-453

  Cahill Smith, Sarah ^a   Li, Jian Mei ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

ageing; Alzheimer's disease; mild cognitive impairment; NADPH oxidase 2; Parkinson's disease; redox signalling

Indexed keywords

ANTIOXIDANT; APOCYNIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; BIOLOGICAL MARKER; CYBB PROTEIN, HUMAN; MEMBRANE PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

AGING; ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DRUG TREATMENT FAILURE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HUMAN; MILD COGNITIVE IMPAIRMENT; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

AGING; ANIMALS; BIOMARKERS; ENDOTHELIUM, VASCULAR; HUMANS; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84906501517     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12357     Document Type: Review

References (160)

1. Lutz W, Sanderson W, Scherbov S,. The coming acceleration of global population ageing. Nature 2008; 451: 716-719. (Pubitemid 351220565)
2. Johri A, Beal MF,. Antioxidants in Huntington's disease. Biochim Biophys Acta 2012; 1822: 664-674.
3. D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H,. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013; 65C: 509-527.
4. Garcia-Garcia A, Zavala-Flores L, Rodriguez-Rocha H, Franco R,. Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease. Antioxid Redox Signal 2012; 17: 1764-1784.
5. Feng Y, Wang X,. Antioxidant therapies for Alzheimer's disease. Oxid Med Cell Longev 2012; 2012: 472932-472948.
6. Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, Squitti R, Perry G,. Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis 2013; 59: 100-110.
7. Sultana R, Perluigi M, Butterfield DA,. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 2009; 118: 131-150.
8. Bedard K, Krause KH,. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313. (Pubitemid 46209993)
9. Starkov AA,. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann N Y Acad Sci 2008; 1147: 37-52.
10. Porasuphatana S, Tsai P, Rosen GM,. The generation of free radicals by nitric oxide synthase. Comp Biochem Physiol Part C Toxicol Pharmacol 2003; 134: 281-289. (Pubitemid 36315651)
11. Kelley E, Khoo N, Hundley N, Malik U,. Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free Radic Biol 2010; 48: 493-498.
12. Dworakowski R, Anilkumar N, Zhang M, Shah AM,. Redox signalling involving NADPH oxidase-derived reactive oxygen species. Biochem Soc Trans 2006; 34: 960-964. (Pubitemid 44796460)
13. Forman HJ, Fukuto JM, Torres M,. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am J Physiol Cell Physiol 2004; 287: C246-256. (Pubitemid 38955213)
14. Gates PE, Strain WD, Shore AC,. Human endothelial function and microvascular ageing. Exp Physiol 2009; 94: 311-316.
15. Gazewood JD, Richards DR, Clebak K,. Parkinson disease: an update. Am Fam Physician 2013; 87: 267-273.
16. Leszek J, Sochocka M, Ga̧siorowski K,. Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease. J Neurol Sci 2012; 323: 25-32.
17. Dickstein DL, Walsh J, Brautigam H, Stockton SD, Gandy S, Hof PR,. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 2010; 77: 82-102.
18. Finkel T, Holbrook NJ,. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-247.
19. Lenaz G,. Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta 1998; 1366: 53-67. (Pubitemid 28467022)
20. Hadley EC, Lakatta EG, Morrison-Bogorad M, Warner HR, Hodes RJ,. The future of aging therapies. Cell 2005; 120: 557-567. (Pubitemid 40269769)
21. Babior BM, Lambeth JD, Nauseef W,. The neutrophil NADPH oxidase. Arch Biochem Biophys 2002; 397: 342-344. (Pubitemid 34852301)
22. Rae J, Newburger PE, Dinauer MC, Noack D, Hopkins PJ, Kuruto R, Curnutte JT,. X-Linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Genet 1998; 62: 1320-1331. (Pubitemid 28307101)
23. Wientjes FB, Segal AW,. NADPH oxidase and the respiratory burst. Semin Cell Biol 1995; 6: 357-365.
24. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD,. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999; 401: 79-82.
25. Banfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH,. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 2004; 279: 46065-46072. (Pubitemid 39491600)
26. Geiszt M, Kopp JB, Varnai P, Leto TL,. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 2000; 97: 8010-8014. (Pubitemid 30460764)
27. Shiose A, Kuroda J, Tsuruya K, Hirai M, Hirakata H, Naito S, Hattori M, Sakaki Y, Sumimoto H,. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 2001; 276: 1417-1423. (Pubitemid 32096573)
28. 2+-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 2001; 276: 37594-37601.
29. De Deken X, Wang D, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE, Miot F,. Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem 2000; 275: 23227-23233. (Pubitemid 30646220)
30. Dupuy C, Ohayon R, Valent A, Noel-Hudson MS, Deme D, Virion A,. Purification of a novel flavoprotein involved in the thyroid NADPH oxidase. Cloning of the porcine and human cdnas. J Biol Chem 1999; 274: 37265-37269.
31. Montezano AC, Burger D, Ceravolo GS, Yusuf H, Montero M, Touyz RM,. Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. Clin Sci (Lond) 2011; 120: 131-141.
32. Takac I, Schroder K, Brandes RP,. The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr Hypertens Rep 2012; 14: 70-78.
33. Choi D-H, Cristõvão AC, Guhathakurta S, Lee J, Joh TH, Beal MF, Kim Y-S,. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal 2012; 16: 1033-1045.
34. Cooney SJ, Bermudez-Sabogal SL, Byrnes KR,. Cellular and temporal expression of NADPH oxidase (NOX) isotypes after brain injury. J Neuroinflammation 2013; 10: 155.
35. Infanger DW, Sharma RV, Davisson RL,. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal 2006; 8: 1583-1596. (Pubitemid 44726333)
36. Sorce S, Krause K-H,. NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal 2009; 11: 2481-2504.
37. Block ML,. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 2008; 9: (Suppl 2): S8.
38. Miller AA, Drummond GR, De Silva TM, Mast AE, Hickey H, Williams JP, Broughton BRS, Sobey CG,. NADPH oxidase activity is higher in cerebral versus systemic arteries of four animal species: role of Nox2. Am J Physiol Heart Circ Physiol 2009; 296: H220-225.
39. Chrissobolis S, Faraci FM,. The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trends Mol Med 2008; 14: 495-502.
40. Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond GR, Sobey CG,. Reduction of cerebral infarct volume by apocynin requires pretreatment and is absent in Nox2-deficient mice. Br J Pharmacol 2009; 156: 680-688.
41. De Silva TM, Brait VH, Drummond GR, Sobey CG, Miller AA,. Nox2 oxidase activity accounts for the oxidative stress and vasomotor dysfunction in mouse cerebral arteries following ischemic stroke. PLoS One 2011; 6: e28393.
42. Kim HA, Brait VH, Lee S, De Silva TM, Diep H, Eisenhardt A, Drummond GR, Sobey CG,. Brain infarct volume after permanent focal ischemia is not dependent on Nox2 expression. Brain Res 2012; 1483: 105-111.
43. Li J-M, Shah AM,. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002; 277: 19952-19960. (Pubitemid 34967517)
44. Li JM, Shah AM,. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Integr Comp Physiol 2004; 287: R1014-1030. (Pubitemid 39391043)
45. Fan LM, Teng L, Li JM,. Knockout of p47 phox uncovers a critical role of p40 phox in reactive oxygen species production in microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29: 1651-1656.
46. Di-Poï N, Fauré J, Grizot S, Molnár G, Pick E, Dagher MC,. Mechanism of NADPH oxidase activation by the Rac/Rho-GDI complex. Biochemistry 2001; 40: 10014-10022. (Pubitemid 32800108)
47. El-Benna J, Dang PM, Gougerot-Pocidalo MA, Marie JC, Braut-Boucher F,. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med 2009; 41: 217-225.
48. Li JM, Fan LM, Christie MR, Shah AM,. Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox phosphorylation and binding to TRAF4. Mol Cell Biol 2005; 25: 2320-2330. (Pubitemid 40354628)
49. phox in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-α. Circ Res 2002; 90: 143-150. (Pubitemid 34627082)
50. Li JM, Shah AM,. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 2003; 278: 12094-12100. (Pubitemid 36800187)
51. - production, vascular tone, and mitogen-activated protein kinase activation. Circulation 2004; 109: 1307-1313. (Pubitemid 38372791)
52. phox phosphorylation at S303-4 or S379 on tumor necrosis factor-α signaling via TRAF4 and MAPK in endothelial cells. Arterioscler Thromb Vasc Biol 2012; 32: 1488-1496.
53. Lener B, Kozieł R, Pircher H, Hütter E, Greussing R, Herndler-Brandstetter D, Hermann M, Unterluggauer H, Jansen-Dürr P,. The NADPH oxidase Nox4 restricts the replicative lifespan of human endothelial cells. Biochem J 2009; 423: 363-374.
54. Schilder YDC, Heiss EH, Schachner D, Ziegler J, Reznicek G, Sorescu D, Dirsch VM,. NADPH oxidases 1 and 4 mediate cellular senescence induced by resveratrol in human endothelial cells. Free Radic Biol Med 2009; 46: 1598-1606.
55. Jeon SM, Lee S-J, Kwon TK, Kim K-J, Bae Y-S,. NADPH oxidase is involved in protein kinase CKII down-regulation-mediated senescence through elevation of the level of reactive oxygen species in human colon cancer cells. FEBS Lett 2010; 584: 3137-3142.
56. Forman HJ, Torres M, Fukuto J,. Redox signaling. Mol Cell Biochem 2002; 234-235: 49-62. (Pubitemid 34777841)
57. Akhtar MW, Sunico CR, Nakamura T, Lipton SA,. Redox regulation of protein function via cysteine S-nitrosylation and its relevance to neurodegenerative diseases. Int J Cell Biol 2012; 2012: 463756.
58. Tickner J, Fan LM, Du J, Meijles D, Li J, Sciences M,. Nox2-derived ROS in PPARγ signaling and cell-cycle progression of lung alveolar epithelial cells. Free Radic Biol Med 2011; 51: 763-772.
59. Fan L, Sawbridge D, George V, Teng L, Bailey A, Kitchen I, Li JM,. Chronic cocaine-induced cardiac oxidative stress and mitogen-activated protein kinase activation: the role of Nox2 oxidase. J Pharmacol Exp Ther 2009; 328: 99-106.
60. Hingtgen SD, Tian X, Yang J, Dunlay SM, Peek AS, Wu Y, Sharma RV, Engelhardt JF, Davisson RL,. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics 2006; 26: 180-191.
61. Liu L, Yang Z, Xu Y, Li J, Xu D, Zhang L, Sun J, Xia S, Zou F, Liu Y,. Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells. PLoS ONE 2013; 8: e73038.
62. Du J, Fan LM, Mai A, Li J-M,. Crucial roles of Nox2-derived oxidative stress in deteriorating insulin receptor and endothelial function in dietary obesity of middle-aged mice. Br J Pharmacol 2013; 170: 1064-1077.
63. 2A receptor attenuates basal and angiotensin II-induced ROS production by Nox2 in endothelial cells. J Biol Chem 2010; 285: 40104-40113.
64. 2 production requires the activation of phosphatidylinositol 3-kinase. J Biol Chem 2000; 275: 10527-10531. (Pubitemid 30202116)
65. Li Q, Spencer NY, Oakley FD, Buettner GR, Engelhardt JF,. Endosomal Nox2 facilitates redox-dependent induction of NF-κB by TNF-α. Antioxid Redox Signal 2009; 11: 1249-1263.
66. Li JM, Fan LM, George VT, Brooks G,. Nox2 regulates endothelial cell cycle arrest and apoptosis via p21cip1 and p53. Free Radic Biol Med 2007; 43: 976-986. (Pubitemid 47241205)
67. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR,. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 1991; 88: 10540-10543. (Pubitemid 21915871)
68. Jolitha AB, Subramanyam MVV, Asha Devi S,. Modification by vitamin E and exercise of oxidative stress in regions of aging rat brain: studies on superoxide dismutase isoenzymes and protein oxidation status. Exp Gerontol 2006; 41: 753-763. (Pubitemid 44223891)
69. Perluigi M, Di Domenico F, Giorgi A, Schininà ME, Coccia R, Cini C, Bellia F, Cambria MT, Cornelius C, Butterfield DA, Calabrese V,. Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. J Neurosci Res 2010; 88: 3498-3507.
70. Dei R, Takeda A, Niwa H, Li M, Nakagomi Y, Watanabe M, Inagaki T, Washimi Y, Yasuda Y, Horie K, Miyata T, Sobue G,. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol 2002; 104: 113-122. (Pubitemid 36075368)
71. Leutner S, Eckert A, Müller WE,. ROS generation, lipid peroxidation and antioxidant enzyme activities in the aging brain. J Neural Transm 2001; 108: 955-967. (Pubitemid 32802093)
72. Clausen A, Doctrow S, Baudry M,. Prevention of cognitive deficits and brain oxidative stress with superoxide dismutase/catalase mimetics in aged mice. Neurobiol Aging 2010; 31: 425-433.
73. Nicolle MM, Gonzalez J, Sugaya K, Baskerville KA, Bryan D, Lund K, Gallagher M, McKinney M,. Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience 2001; 107: 415-431. (Pubitemid 33079118)
74. Quick KL, Ali SS, Arch R, Xiong C, Wozniak D, Dugan LL,. A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice. Neurobiol Aging 2008; 29: 117-128. (Pubitemid 350102712)
75. Park L, Anrather J, Girouard H, Zhou P, Iadecola C,. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab 2007; 27: 1908-1918. (Pubitemid 350129160)
76. Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MMS, Shankar SK,. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochem Res 2012; 37: 358-369.
77. Van der Loo B, Bachschmid M, Spitzer V, Brey L, Ullrich V, Lüscher TF,. Decreased plasma and tissue levels of vitamin C in a rat model of aging: implications for antioxidative defense. Biochem Biophys Res Commun 2003; 303: 483-487. (Pubitemid 36349195)
78. Van der Loo B, Labugger R, Aebischer CP, Bachschmid M, Spitzer V, Kilo J, Altwegg L, Ullrich V, Lüscher TF,. Age-related changes of vitamin A status. J Cardiovasc Pharmacol 2004; 43: 26-30. (Pubitemid 38032060)
79. Morrison CD, Pistell PJ, Ingram DK, Johnson WD, Liu Y, Fernandez-Kim SO, White CL, Purpera MN, Uranga RM, Bruce-Keller AJ, Keller JN,. High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling. J Neurochem 2010; 114: 1581-1589.
80. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST,. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142.
81. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E,. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308. (Pubitemid 29120227)
82. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C,. Progression of mild cognitive impairment to dementia in clinic- vs. community-based cohorts. Arch Neurol 2009; 66: 1151-1157.
83. Yesavage JA, O'Hara R, Kraemer H, Noda A, Taylor JL, Ferris S, Gély-Nargeot M-C, Rosen A, Friedman L, Sheikh J, Derouesné C,. Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res 2002; 36: 281-286. (Pubitemid 34764052)
84. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR,. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005; 64: 1152-1156.
85. Torres LL, Quaglio NB, de Souza GT, Garcia RT, Dati LMM, Moreira WL, Loureiro AP, de Souza-Talarico JN, Smid J, Porto CS, Bottino CM, Nitrini R, Barros SB, Camarini R, Marcourakis T,. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2011; 26: 59-68.
86. Baldeiras I, Santana I, Proença MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR,. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 2008; 15: 117-128.
87. Lõpez N, Tormo C, De Blas I, Llinares I, Alom J,. Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 2013; 33: 823-829.
88. Praticò D, Clark CM, Liun F, Rokach J, Lee VY-M, Trojanowski JQ,. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002; 59: 972-976. (Pubitemid 34640757)
89. Lee LK, Shahar S, Rajab N, Yusoff NAM, Jamal RA, Then SM,. The role of long chain omega-3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment: a case-control study. J Nutr Biochem 2013; 24: 803-808.
90. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R,. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 2006; 397: 170-173.
91. Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, Markesbery WR, Sultana R,. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 2007; 1148: 243-248. (Pubitemid 46602178)
92. Cha H-N, Kim Y-W, Kim J-Y, Kim Y-D, Song IH, Min K-N, Park S-Y,. Lack of inducible nitric oxide synthase does not prevent aging-associated insulin resistance. Exp Gerontol 2010; 45: 711-718.
93. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron P, Bresolin N, Scarpini E,. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2006; 27: 262-269. (Pubitemid 43038550)
94. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P,. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003; 24: 915-919. (Pubitemid 36962976)
95. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C,. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2010; 469: 6-10.
96. Dugan LL, Ali SS, Shekhtman G, Roberts AJ, Lucero J, Quick KL, Behrens MM,. IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase. PLoS ONE 2009; 4: e5518.
97. Bruce-Keller AJ, Gupta S, Parrino TE, Knight AG, Ebenezer PJ, Weidner AM, LeVine H, Keller JN, Markesbery WR,. NOX activity is increased in mild cognitive impairment. Antioxid Redox Signal 2010; 12: 1371-1382.
98. Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, Younkin L, Younkin S, Carlson G, McEwen BS, Iadecola C,. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A 2008; 105: 1347-1352. (Pubitemid 351397056)
99. Ali SS, Young JW, Wallace CK, Gresack J, Jeste DV, Geyer MA, Dugan LL, Risbrough VB,. Initial evidence linking synaptic superoxide production with poor short-term memory in aged mice. Brain Res 2011; 1368: 65-70.
100. 1-42 and NOX activation. Neurobiol Dis 2011; 44: 317-326.
101. Ansari MA, Scheff SW,. NADPH-oxidase activation and cognition in Alzheimer disease progression. Free Radic Biol Med 2011; 51: 171-178.
102. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: DSM-IV-TR®. Washington DC: American Psychiatric Association, 2000.
103. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH,. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
104. Ittner LM, Götz J,. Amyloid-β and tau- A toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72.
105. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S,. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun 2000; 273: 5-9. (Pubitemid 30426853)
106. Zekry D, Epperson TK, Krause K-H,. A role for NOX NADPH oxidases in Alzheimer's disease and other types of dementia? IUBMB Life 2003; 55: 307-313. (Pubitemid 36975540)
107. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD,. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-1577. (Pubitemid 30161512)
108. Carrano A, Hoozemans JJM, van der Vies SM, Rozemuller AJM, van Horssen J, de Vries HE,. Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 2011; 15: 1167-1178.
109. Carrano A, Hoozemans JJM, van der Vies SM, van Horssen J, de Vries HE, Rozemuller AJM,. Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis 2012; 10: 329-331.
110. Heumüller S, Wind S, Barbosa-Sicard E, Schmidt HHHW, Busse R, Schröder K, Brandes RP,. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008; 51: 211-217. (Pubitemid 351159930)
111. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ,. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 1994; 11: 95-102.
112. Ximenes VF, Kanegae MPP, Rissato SR, Galhiane MS,. The oxidation of apocynin catalyzed by myeloperoxidase: proposal for NADPH oxidase inhibition. Arch Biochem Biophys 2007; 457: 134-141. (Pubitemid 46048700)
113. Touyz RM,. Apocynin, NADPH oxidase, and vascular cells: a complex matter. Hypertension 2008; 51: 172-174. (Pubitemid 351159922)
114. Johnson DK, Schillinger KJ, Kwait DM, Hughes CV, McNamara EJ, Ishmael F, O'Donnell RW, Chang M-M, Hogg MG, Dordick JS, Santhanam L, Ziegler LM, Holland JA,. Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium 2002; 9: 191-203. (Pubitemid 35021589)
115. Dumont M, Stack C, Elipenhali C, Calingasan NY, Wille E, Beal MF,. Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2011; 492: 150-154.
116. Wang Q, Tompkins KD, Simonyi A, Korthuis RJ, Sun AY, Sun GY,. Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus. Brain Res 2006; 1090: 182-189. (Pubitemid 43817927)
117. Harraz MM, Marden JJ, Zhou W, Zhang Y, Williams A, Sharov VS, Nelson K, Luo M, Paulson H, Schöneich C, Engelhardt JF,. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest 2008; 118: 659-670. (Pubitemid 351206555)
118. Qin B, Cartier L, Dubois-Dauphin M, Li B, Serrander L, Krause K-H,. A key role for the microglial NADPH oxidase in APP-dependent killing of neurons. Neurobiol Aging 2006; 27: 1577-1587. (Pubitemid 44349157)
119. Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CYD, Landreth G,. Fibrillar β-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem 2006; 281: 20842-20850. (Pubitemid 44115425)
120. Surace MJ, Block ML,. Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell Mol Life Sci 2012; 69: 2409-2427.
121. Shelat PB, Chalimoniuk M, Wang J-H, Strosznajder JB, Lee JC, Sun AY, Simonyi A, Sun GY,. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 2008; 106: 45-55. (Pubitemid 351840199)
122. Sun GY, Horrocks LA, Farooqui AA,. The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J Neurochem 2007; 103: 1-16. (Pubitemid 47404193)
123. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G,. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 1999; 72: 2053-2058. (Pubitemid 29186010)
124. De la Monte SM, Wands JR,. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006; 9: 167-181. (Pubitemid 44088244)
125. Bodles AM, Barger SW,. Secreted β-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol Aging 2005; 26: 9-16. (Pubitemid 39600586)
126. Lee SY, Lee JW, Lee H, Yoo HS, Yun YP, Oh KW, Ha TY, Hong JT,. Inhibitory effect of green tea extract on β-amyloid-induced PC12 cell death by inhibition of the activation of NF-κB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Brain Res Mol Brain Res 2005; 140: 45-54. (Pubitemid 41446146)
127. Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani LG, Ferrario M, Borsani G, Spano P, Pizzi M,. NF-κB pathway: a target for preventing β-amyloid (Aβ)-induced neuronal damage and Aβ42 production. Eur J Neurosci 2006; 23: 1711-1720.
128. Calabresi P, Castrioto A, Di Filippo M, Picconi B,. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet Neurol 2013; 12: 811-821.
129. Jankovic J,. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-376. (Pubitemid 351441488)
130. Harrigan TJ, Abdullaev IF, Jourd'heuil D, Mongin AA,. Activation of microglia with zymosan promotes excitatory amino acid release via volume-regulated anion channels: the role of NADPH oxidases. J Neurochem 2008; 106: 2449-2462.
131. Zhang W, Wang T, Qin L, Gao H-M, Wilson B, Ali SF, Zhang W, Hong J-S, Liu B,. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004; 18: 589-591.
132. Qin L, Liu Y, Hong J-S, Crews FT,. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 2013; 61: 855-868.
133. Wu D-C, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S,. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 2003; 100: 6145-6150. (Pubitemid 36576945)
134. Huh SH, Chung YC, Piao Y, Jin MY, Son HJ, Yoon NS, Hong JY, Pak YK, Kim YS, Hong JK, Hwang O, Jin BK,. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. J Immunol 2011; 187: 960-969.
135. Liang L-P, Huang J, Fulton R, Day BJ, Patel M,. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity in vivo. J Neurosci 2007; 27: 4326-4333. (Pubitemid 46640723)
136. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C,. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009; 12: 826-828.
137. Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, Kalyanaraman B,. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse. Neurosci Lett 2013; 549: 57-62.
138. Chongthammakun V, Sanvarinda Y, Chongthammakun S,. Reactive oxygen species production and MAPK activation are implicated in tetrahydrobiopterin- induced SH-SY5Y cell death. Neurosci Lett 2009; 449: 178-182.
139. Newhouse K, Hsuan S-L, Chang SH, Cai B, Wang Y, Xia Z,. Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol Sci 2004; 79: 137-146. (Pubitemid 38660257)
140. Ferrer I, Blanco R, Carmona M, Puig B, Barrachina M, Gõmez C, Ambrosio S,. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J Neural Transm 2001; 108: 1383-1396. (Pubitemid 34020444)
141. 2-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 2000; 75: 1200-1208. (Pubitemid 30660510)
142. Karunakaran S, Diwakar L, Saeed U, Agarwal V, Ramakrishnan S, Iyengar S, Ravindranath V,. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by α-lipoic acid. FASEB J 2007; 21: 2226-2236. (Pubitemid 47026457)
143. Thomas T, Timmer M, Cesnulevicius K, Hitti E, Kotlyarov A, Gaestel M,. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation-relevance in a mouse model of Parkinson's disease. J Neurochem 2008; 105: 2039-2052. (Pubitemid 351678515)
144. Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, Meka DP, Seth P, Ravindranath V,. Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J Neurosci 2008; 28: 12500-12509.
145. Duan W, Zhu X, Ladenheim B, Yu Q, Guo Z, Oyler J, Cutler RG, Cadet JL, Greig NH, Mattson MP,. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002; 52: 597-606. (Pubitemid 35246863)
146. Wang H-M, Wang L-W, Liu X-M, Li C-L, Xu S-P, Farooq A-D,. Neuroprotective effects of forsythiaside on learning and memory deficits in senescence-accelerated mouse prone (SAMP8) mice. Pharmacol Biochem Behav 2013; 105: 134-141.
147. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE,. The antioxidants α-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003; 84: 1173-1183. (Pubitemid 36330669)
148. Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, Baudry M,. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci U S A 2003; 100: 8526-8531. (Pubitemid 36842578)
149. Raghavendra V, Kulkarni SK,. Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks. Free Radic Biol Med 2001; 30: 595-602. (Pubitemid 32280785)
150. Praticò D, Uryu K, Leight S, Trojanoswki JQ, Lee VM,. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001; 21: 4183-4187. (Pubitemid 32538543)
151. Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG,. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J Neuroinflammation 2012; 9: 241.
152. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K,. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2007; 104: 18754-18759. (Pubitemid 350210769)
153. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR,. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 2006; 22: 223-232.
154. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA,. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 2006; 22: 76-87.
155. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA,. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 2005; 93: 953-962. (Pubitemid 40695754)
156. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA,. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003; 85: 1394-1401. (Pubitemid 36702552)
157. Isobe C, Abe T, Terayama Y,. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegener. Neurosci Lett 2010; 469: 159-163.
158. White LR, Toft M, Kvam SN, Farrer MJ, Aasly JO,. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J Neurosci Res 2007; 85: 1288-1294. (Pubitemid 46724372)
159. Prigione A, Begni B, Galbussera A, Beretta S, Brighina L, Garofalo R, Andreoni S, Piolti R, Ferrarese C,. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol Dis 2006; 23: 36-43. (Pubitemid 43903629)
160. Serra JA, Domínguez RO, de Lustig ES, Guareschi EM, Famulari AL, Bartolomé EL, Marschoff ER,. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J Neural Transm 2001; 108: 1135-1148. (Pubitemid 33022763)